2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
ABVC BioPharma said on August 3, 2026 that it has postponed the previously announced distribution of BioKey (Cayman), Inc. ordinary shares, which had been scheduled for the same day. The company needs more time to complete administrative, regulatory and tax-related matters, and it is coordinating with Nasdaq, DTC and its transfer agent on revised mechanics and new dates.
Distribution scheduled for August 3, 2026 has been postponed; no new date has been set
Record date is unchanged and the distribution ratio remains 0.169464 BioKey ordinary shares per ABVC common share
The previously announced ex-dividend date no longer applies and will be revised; the company will announce the new dates once finalized
Lantheus Holdings entered a merger agreement under which Curium US Holdings would acquire the company, with Lantheus surviving as a wholly owned subsidiary of Curium's parent. Shareholders would receive $102.50 per share in cash plus one contingent value right worth up to $12.00 per share upon certain commercial milestones, so the deal would end their ownership of the stock and its Nasdaq listing.
Cash consideration of $102.50 per share plus one CVR paying up to $12.00 in cash on specified commercial milestones
Closing requires stockholder approval, expiration or termination of the HSR waiting period, and other customary conditions; no financing condition
Either party may terminate if the merger is not completed by May 2, 2027, subject to extensions
Ares Commercial Real Estate reported GAAP net income of $4.4 million, or $0.08 per diluted share, for the quarter ended June 30, 2026, compared with a net loss of $11.0 million, or $0.20 per share, a year earlier. The company also declared a $0.15 per share dividend for the third quarter of 2026, unchanged from the prior quarters, and the results are supported by higher total revenue of $14.4 million.
GAAP net income of $4.4 million, or $0.08 per diluted share, for Q2 2026, versus a net loss of $11.0 million, or $0.20 per share, in Q2 2025
Distributable Earnings (a non-GAAP measure) of $6.9 million, or $0.12 per diluted share, for Q2 2026
Total revenue of $14.4 million for Q2 2026, up from $12.6 million in Q2 2025
Third quarter 2026 dividend of $0.15 per share declared August 4, 2026, payable October 15, 2026 to holders of record as of September 30, 2026
TETRA Technologies reported second-quarter 2026 revenue of $185.7 million, up 7% from a year earlier and 19% from the first quarter, but income from continuing operations of $10.2 million was below the $11.3 million reported a year earlier. Adjusted EBITDA was $31.9 million, compared with $36.2 million in the second quarter of 2025, and the company raised $108.2 million in net proceeds from a June share sale and approved a final investment decision for its Arkansas Bromine Project.
Revenue $185.7 million vs $173.9 million a year earlier and $156.3 million in the first quarter of 2026
Net income per share from continuing operations $0.07 vs $0.08 a year earlier; adjusted net income per share $0.08 vs $0.09
Adjusted EBITDA $31.9 million vs $36.2 million a year earlier; Completion Fluids & Products Adjusted EBITDA margin 26.4% vs 36.9%
June 2026 issuance of about 12.4 million shares at $9.25 produced $108.2 million in net proceeds; Board approved Arkansas Bromine Project FID on May 28, 2026
Duke Energy reported second-quarter 2026 reported EPS of $1.38 and adjusted EPS of $1.43, up from $1.25 in the second quarter of 2025. The company reaffirmed its 2026 adjusted EPS guidance of $6.55 to $6.80, so shareholders see higher quarterly earnings with no change to the full-year outlook.
Second-quarter 2026 reported EPS was $1.38 and adjusted EPS was $1.43, compared with $1.25 for both measures in the second quarter of 2025.
Reported results include $39 million after tax, or $0.05 per share, in charges related to regulatory settlements, excluded from adjusted EPS.
Electric Utilities and Infrastructure adjusted segment income was $1,310 million, compared with $1,194 million a year earlier.
2026 adjusted EPS guidance of $6.55 to $6.80 was reaffirmed; the long-term adjusted EPS growth rate of 5% to 7% through 2030 was also reaffirmed.
Leidos reported second-quarter fiscal 2026 revenue of $4.56 billion, up 7% year-over-year, while GAAP net income fell 9% to $356 million and GAAP diluted EPS fell to $2.81 from $3.01. The company raised its fiscal 2026 guidance for revenue, non-GAAP diluted EPS and operating cash flow, but GAAP profit declined from the prior year.
Revenue $4.56 billion, up 7% (4% organic); GAAP diluted EPS $2.81 vs. $3.01 a year earlier
Non-GAAP diluted EPS $3.26, up 2%; adjusted EBITDA $631 million, down 2%, with margin of 13.8% vs. 15.2%
On July 31, 2026, GoDaddy subsidiaries signed an amendment that replaces their existing $1.0 billion revolving credit facility with a new $1.2 billion facility. The filing says the new facility carries a stated maturity of July 31, 2031, and keeps the same leverage covenant as the prior facility, so the change mainly affects the company's borrowing capacity and financing terms.
New revolving credit facility of $1.2 billion replaces the existing $1.0 billion facility
Margin of 1.25% to 1.75% for term SOFR, EURIBOR or SONIA-based loans, and 0.25% to 0.75% for U.S. dollar base rate loans, both based on first lien net leverage ratio
Stated maturity of July 31, 2031, with a springing maturity tied to certain term loans or debt issuances above $500 million
Covenant requires a first lien net leverage ratio of no more than 5.75:1.00 when utilization is at least 40% of commitments
Ainos reported second-quarter 2026 results for the period ended June 30, 2026. Revenue fell from $4,663 a year earlier to $152, and the net loss widened to $4,594,731 from $4,084,990, although the per-share loss narrowed to $0.62 from $0.99 as the share count rose. Shareholders face a sharp revenue decline, $11,000,000 in convertible notes now classified as current liabilities, and stockholders' equity that fell to $3,283,985 from $7,562,582.
Q2 2026 revenue was $152, versus $4,663 in Q2 2025; six-month revenue was $313, versus $110,870.
Q2 2026 net loss was $4,594,731, versus $4,084,990 a year earlier; basic and diluted loss per share was $0.62, versus $0.99.
Cash and cash equivalents rose to $1,422,912 at June 30, 2026, from $417,353 at December 31, 2025.
Convertible notes payable of $11,000,000 and a loan payable of $2,812,940 were current liabilities at June 30, 2026.
Reformation Inc. completed its initial public offering on July 31, 2026, selling 14,062,500 shares of common stock at $15.00 per share, including 4,583,679 shares sold by selling stockholders. The company said it received no proceeds from the selling stockholders' shares, and it reported aggregate gross proceeds of approximately $210.9 million before underwriting discounts, commissions and estimated offering expenses. Its amended and restated certificate of incorporation and bylaws took effect on the same date, which sets the governing rules for shareholders going forward.
IPO closed July 31, 2026: 14,062,500 shares at $15.00 per share
Includes 4,583,679 shares sold by selling stockholders; the company received no proceeds from those shares
Aggregate gross proceeds of approximately $210.9 million before underwriting discounts and estimated expenses
Amended and restated certificate of incorporation and bylaws effective July 31, 2026
Obsidian Therapeutics completed its mergers with Galera Therapeutics on August 3, 2026, alongside a $350 million private placement. Legacy Obsidian holders now own about 51.6% of the combined company, Galera holders about 1.2%, and private placement investors about 47.2%, so existing shareholders are substantially diluted. The filing also says the company's 2025 going concern doubt and its prior losses remain risk factors.
Mergers consummated at 8:30 a.m. ET on August 3, 2026; the company was renamed Obsidian Therapeutics, Inc.
Concurrent PIPE Financing raised $350.0 million; about 29,165,559 shares were issued to investors.
Post-closing ownership: Legacy Obsidian about 51.6%, Legacy Galera about 1.2%, PIPE investors about 47.2%.
Shares expected to begin trading on Nasdaq under OBX on August 4, 2026; CVRs issued to Galera holders of record as of July 31, 2026.
CVG reported second-quarter 2026 revenue of $195.2 million, up 13.5% from a year earlier, and a net loss from continuing operations of $8.7 million, or $(0.25) per diluted share, compared with a loss of $(0.12) per share in the prior-year quarter. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance, though the larger loss, which includes a $3.4 million warrant liability charge, is a concern for shareholders.
Revenues of $195.2 million, up from $172.0 million in Q2 2025, driven by all three segments.
Net loss from continuing operations of $8.7 million, or $(0.25) per diluted share, versus $(0.12) a year earlier; includes a $3.4 million pre-tax warrant liability revaluation expense.
2026 revenue outlook raised to $725 million-$755 million from $660 million-$700 million; Adjusted EBITDA outlook raised to $26 million-$31 million from $24 million-$30 million.
Net proceeds of approximately $11.6 million from the at-the-market equity program were used to pay down the term loan.
Stoke Therapeutics filed a prospectus supplement on August 3, 2026, covering the offer and sale of up to $200 million of common stock through Cantor Fitzgerald under an existing May 2022 sales agreement. The filing makes new share issuance possible, which could dilute existing shareholders, but the filing itself does not state how many shares have been sold or at what prices.
Prospectus supplement filed August 3, 2026 covers up to $200,000,000 of Placement Shares.
Sales run through Cantor Fitzgerald & Co. under the Controlled Equity Offering sales agreement dated May 20, 2022.
Offering is made under an automatic shelf registration statement (Form S-3ASR, File No. 333-294402) filed March 18, 2026.
Fenwick & West LLP legal opinion is filed as Exhibit 5.1.
Camden Property Trust said its Executive Vice Chairman, D. Keith Oden, is retiring from that role effective August 31, 2026. Mr. Oden will remain on the company's Board of Trust Managers, so his board seat continues.
D. Keith Oden is retiring as Executive Vice Chairman of the Board of Trust Managers effective August 31, 2026.
Mr. Oden will continue to serve as a member of the Board of Trust Managers.
The filing does not name a successor or describe any change in compensation.
Viemed Healthcare reported second-quarter 2026 net revenue of $78.1 million, a company record and up 23.9% from a year earlier, while net income attributable to the company fell to $2.8 million from $3.2 million. The company raised the low end of its full-year net revenue guidance but cut its Adjusted EBITDA guidance by $1 million at both ends of the range, to $64 million to $68 million.
Q2 2026 net revenue was $78.1 million, up $15.0 million, or 23.9%, from the prior-year quarter.
Net income attributable to Viemed was $2.8 million, or $0.07 per diluted share, versus $3.2 million in Q2 2025.
Adjusted EBITDA was $13.7 million, down 4.0% year over year; the prior-year period included a $1.0 million non-recurring gain.
2026 guidance: net revenue $314 million to $320 million (previously $312 million to $320 million); Adjusted EBITDA $64 million to $68 million (previously $65 million to $69 million).
On August 3, 2026, Intuitive Machines closed its acquisition of Goonhilly Earth Station Limited in the UK and COMSAT LLC in the US, which the company says expands its ground station network. The UK consideration was £37.0 million, half in cash and half in 960,649 shares of Class A common stock, and both deals are subject to post-closing adjustments. The filing does not give revenue or earnings figures for the businesses acquired.
UK acquisition of Goonhilly Earth Station Limited: £37.0 million, split equally between cash and stock.
Stock portion: 960,649 shares of Class A common stock; UK consideration is subject to post-closing adjustments.
COMSAT LLC acquired for a base cash price of $10 million plus expense reimbursement, subject to adjustments for cash, debt, working capital and specified capital expenditures.
Company plans to use the expanded network for the upcoming IM-3 and Altus-1 missions.
The Andersons reported second quarter 2026 net income attributable to the company of $56.6 million, or $1.65 per diluted share, compared with $7.9 million, or $0.23 per diluted share, a year earlier. Adjusted diluted EPS was $2.15 versus $0.24, and quarterly sales and merchandising revenues were $3.10 billion, down slightly from $3.14 billion, so the headline measures point in different directions. The company also gave a full-year adjusted effective tax rate estimate of approximately 14% to 18% and will hold a conference call on August 4, 2026.
Net income attributable to the company was $56.6 million, or $1.65 per diluted share, versus $7.9 million, or $0.23, in Q2 2025.
Adjusted diluted EPS was $2.15 versus $0.24; adjusted EBITDA was $140.3 million versus $65.2 million.
Sales and merchandising revenues were $3.10 billion versus $3.14 billion in Q2 2025.
Renewables reported record second quarter pretax income of $65 million; the webcast is set for August 4, 2026 at 8:30 a.m. ET.
onsemi reported second-quarter 2026 revenue of $1,603.5 million, up 9% from a year earlier, with GAAP net income attributable to the company of $226.8 million versus $170.3 million in the second quarter of 2025. It also guided third-quarter 2026 revenue to $1,650 million to $1,750 million and GAAP diluted EPS to $0.79 to $0.91, and repurchased $332 million of shares in the quarter.
Q2 2026 revenue of $1,603.5 million, up 9% year over year and up from $1,513.3 million in Q1 2026
GAAP diluted EPS of $0.56 versus $0.41 in Q2 2025; non-GAAP diluted EPS of $0.74
Q3 2026 outlook: revenue of $1,650 million to $1,750 million and GAAP diluted EPS of $0.79 to $0.91
Free cash flow of $425.4 million and share repurchases of $332 million in the quarter
Tripadvisor signed an equity purchase agreement on August 2, 2026, to sell its European restaurant reservation platform TheFork to American Express Travel Related Services Company for $700 million in cash, subject to adjustments. Closing requires regulatory approvals, including European antitrust clearances, and is expected by the end of 2026, so shareholders will not see the proceeds until then and the deal could still fail.
Buyer will pay $700 million in cash on hand, subject to certain adjustments.
If the deal is terminated for failure to clear regulatory or antitrust hurdles, Buyer owes a $35 million reverse termination fee.
The Company completed the French works council consultation on July 30, 2026, and gave notice of exercise of the put option on August 1, 2026.
Atlas Energy Solutions reported second-quarter 2026 results on August 3, 2026. Revenue rose 10.4% from the first quarter to $293.2 million and the net loss narrowed to $25.1 million from $47.3 million, but the net loss was wider than the $5.6 million reported a year earlier and adjusted EBITDA of $49.5 million was below the $71.2 million in the second quarter of 2025. The company also said it signed its first long-term behind-the-meter power contract, for 120 MWs expected to come online at the end of the first quarter of 2027.
Total revenue of $293.2 million, up from $265.6 million in Q1 2026 and $288.7 million in Q2 2025.
Net loss of $25.1 million, compared with $47.3 million in Q1 2026 and $5.6 million in Q2 2025.
Adjusted EBITDA of $49.5 million, up from $29.9 million in Q1 2026 but down from $71.2 million in Q2 2025.
Total liquidity of $292.9 million as of June 30, 2026, including $168.2 million in cash; management expects 180 to 200 MWs of oilfield power deployed by the end of 2026.
Cue Biopharma's board appointed James Ahlers as Chief Financial Officer, effective July 30, 2026, and he will serve as the company's principal financial officer. Ahlers previously served as consulting CFO to life sciences companies and spent nearly two decades as CFO of Intarcia Therapeutics. The filing sets his annualized base salary at $450,000 and describes inducement equity grants and severance terms.
Appointment effective July 30, 2026; Ahlers, age 62, will serve as principal financial officer.
Annualized base salary of $450,000, with a discretionary annual bonus target of up to 45% of base salary.
Initial option exercise price of $30.40, the Nasdaq closing price on the effective date; RSU award for 25,500 shares; grants vest quarterly over four years.
Qualifying termination entitles him to a lump sum of nine months' base salary plus a prorated target bonus.
Newbridge Acquisition Limited (NBRG) entered into a Business Combination Agreement on August 3, 2026, with Startech Group Inc., a Delaware company with AQP Water and StarOS AI platform segments. Startech equityholders would receive an aggregate of $1,000,000,000 in Parent common shares at $10.00 per share, and the deal requires shareholder approvals and an effective registration statement before closing.
Aggregate merger consideration of $1,000,000,000 divided by $10.00 per share, which the press release describes as 100,000,000 shares
Newbridge will re-domicile from the British Virgin Islands to Delaware and be renamed Startech Inc. before closing
Closing requires approval by shareholders of both companies, an effective Form S-4, and conditional Nasdaq listing approval
Either party may terminate if closing has not occurred by November 2, 2027; Startech must deliver audited fiscal year ended June 30, 2026 financial statements within 60 days of signing
National Presto reported second quarter 2026 net sales of $146.6 million, up from $120.4 million a year earlier, and net earnings of $15.9 million, or $2.21 per share, compared with $5.2 million, or $0.72 per share. Defense segment sales rose 27.2%, while Housewares/Small Appliances sales fell 6.2%, and part of that segment's operating earnings came from a tariff refund.
Q2 2026 net sales $146.6 million vs. $120.4 million in Q2 2025
Q2 2026 net earnings $15.9 million, $2.21 per share, vs. $5.2 million, $0.72 per share
Six months ended July 5, 2026: net sales $265.2 million and net earnings $22.5 million, $3.14 per share
Housewares/Small Appliance operating earnings of $2.2 million, mostly from a refund of tariffs the Supreme Court declared unauthorized
Cabot reported fiscal third-quarter 2026 net sales of $982 million, up from $923 million a year earlier, but diluted EPS fell to $0.12 from $1.86 after $1.55 per share of after-tax certain items, mainly restructuring and employee benefit plan termination charges. The company tightened its fiscal 2026 Adjusted EPS guidance to $6.15 to $6.45 from $6.00 to $6.50, and announced that Erica McLaughlin will succeed Sean Keohane as President and CEO effective October 1, 2026.
Third-quarter net sales rose to $982 million from $923 million; Adjusted EPS was $1.67 versus $1.90 a year earlier.
Net income attributable to Cabot was $6 million, down from $101 million, after $78 million of certain items in the quarter.
Fiscal 2026 Adjusted EPS guidance narrowed to $6.15 to $6.45 per share from $6.00 to $6.50.
Keohane will retire; McLaughlin is elected President, CEO and a Board member effective October 1, 2026.
Terex reported second-quarter 2026 results on July 30, 2026, with pro-forma sales up 8.5% to $2.2 billion and adjusted EBITDA up $26 million to $269 million. The company raised its full-year 2026 outlook to sales of $7.9 billion to $8.2 billion, adjusted EBITDA of $960 million to $1.0 billion, and adjusted EPS of $4.70 to $5.10, and said it is working through a strategic review of the Aerials segment with interest from multiple parties.
Q2 pro-forma sales rose 8.5% to $2.2 billion; adjusted EBITDA rose $26 million, or 10.7%, to $269 million, with adjusted EBITDA margin of 12.0%
Q2 adjusted EPS was $1.37, including a net benefit of $8 million from IEEPA tariff refunds offset by a one-time unfavorable customs-related accrual
Full-year 2026 guidance: sales $7.9 billion to $8.2 billion, adjusted EBITDA $960 million to $1.0 billion, adjusted EPS $4.70 to $5.10, free cash flow $300 million to $350 million
Company says it has interest from multiple parties in the Aerials strategic review and will provide no specific details until the process unfolds
Vornado reported second-quarter 2026 revenue of $462.2 million, up from $441.4 million a year earlier, and FFO as adjusted of $131.1 million, or $0.67 per diluted share, up from $0.56. GAAP net income attributable to common shareholders fell to $16.4 million, or $0.08 per diluted share, from $743.8 million, or $3.70, mainly because of an $803.2 million gain on the 770 Broadway master lease with NYU in the prior-year quarter.
Q2 2026 revenue was $462.2 million versus $441.4 million in Q2 2025.
FFO as adjusted was $131.1 million, or $0.67 per diluted share, versus $113.3 million, or $0.56, a year earlier.
GAAP net income attributable to common shareholders was $16.4 million, or $0.08 per diluted share, versus $743.8 million, or $3.70, in the prior-year quarter.
For the six months ended June 30, 2026, the company reported a net loss attributable to common shareholders of $6.4 million, or $0.03 per diluted share.
Innovex reported second-quarter 2026 revenue of $245 million, up 9% from a year earlier, and net income of $25 million, or $0.36 per diluted share, after a net loss in the first quarter tied to a $48.8 million legal settlement provision. The company also gave third-quarter guidance of $260 to $270 million in revenue and $51 to $57 million in Adjusted EBITDA, which includes TCO, a business it acquired on July 1, 2026 for $95 million in cash and stock.
Q2 2026 revenue was $244.9 million, up 2% from Q1 2026 and up 9% from Q2 2025.
Net income was $25.0 million ($0.36 per diluted share), compared with a net loss of $16.7 million in Q1 2026 and net income of $15.3 million in Q2 2025.
Adjusted EBITDA was $48.0 million, down from $49.3 million in Q1 2026 and up from $46.6 million in Q2 2025.
Cash and cash equivalents were $222 million at June 30, 2026, with no bank debt; free cash flow was $30.4 million.
Nuwellis, Inc. sold 1,310,890 common shares at $2.59 per share in a registered direct offering, with gross proceeds expected to be about $3.4 million before placement agent fees and expenses. The offering closed on August 3, 2026, and investors also received warrants to buy up to 1,310,890 more shares at $2.59, which adds potential future dilution for existing shareholders.
Registered direct offering of 1,310,890 shares at $2.59 per share, with gross proceeds expected to be about $3.4 million before fees and expenses
Concurrent private placement of warrants to buy up to 1,310,890 shares at $2.59, exercisable immediately with a five-year term from registration effectiveness
Placement agent Ladenburg Thalmann & Co. Inc. receives a cash fee of 9.0% of gross proceeds plus warrants equal to 3.0% of shares issued
Company separately received $3.1 million from warrant exercises tied to its June 2026 public offering, according to the press release
Teleflex completed the sale of its Original Equipment Manufacturing and Development Services (OEM) business on August 3, 2026, for $1.5 billion in cash, subject to adjustment. The company estimates after-tax proceeds of about $1.25 billion and intends to use the net proceeds for debt reduction and share repurchases. Teleflex will give updated 2026 guidance with its second-quarter results on August 6, 2026.
Sale closed August 3, 2026, for $1.5 billion in cash, subject to adjustment under the agreement dated December 9, 2025
Estimated after-tax proceeds of about $1.25 billion
Company priorities include $800 million of debt reduction and completing its $1 billion share repurchase authorization
Updated 2026 financial guidance to be provided with second-quarter results on August 6, 2026
HealthStream reported second-quarter 2026 revenue of $83.7 million, up 12.5% and a company record, with net income of $6.7 million and diluted EPS of $0.23, both up from the second quarter of 2025. The company raised its full-year 2026 revenue and adjusted EBITDA guidance but lowered its net income guidance, and declared a quarterly dividend of $0.035 per share.
Q2 2026 revenue $83.7 million, up 12.5% from $74.4 million; operating income $8.3 million, up 41.4%
Diluted EPS $0.23 versus $0.18 a year earlier; net income $6.7 million, up 23.8%
2026 revenue guidance raised to $327.0 million to $332.0 million from $323.0 million to $330.0 million
2026 net income guidance lowered to $19.5 million to $22.2 million from $20.4 million to $22.8 million; adjusted EBITDA guidance raised to $74.0 million to $78.0 million
Dorman Products reported second-quarter 2026 net sales of $544.6 million, up 0.7%, and diluted EPS of $2.93, up 53%, helped by IEEPA tariff cost recovery. The company raised its 2026 diluted and adjusted EPS guidance but lowered its net sales growth outlook to 3% to 5% from 7% to 9%.
Q2 net sales of $544.6 million, up 0.7%; gross margin 46.1% vs. 40.6% a year earlier
Diluted EPS $2.93 vs. $1.91; adjusted diluted EPS $3.08 vs. $2.06, with IEEPA tariff recovery adding $1.18 per share
2026 guidance: net sales growth cut to 3% to 5% from 7% to 9%; diluted EPS raised to $7.93 to $8.23 from $7.57 to $7.97
Repurchased $47 million of shares in the quarter; conference call on August 4, 2026 at 8:00 a.m. ET
Alamo Group reported second-quarter 2026 net sales of $450.7 million, up 7.6% from a year earlier, with Industrial Equipment sales up 12.8%. GAAP diluted EPS was $2.55, nearly flat against $2.57, while adjusted diluted EPS rose 7.2% to $2.82 after excluding items such as restructuring expenses. The Board also adopted amended and restated bylaws effective July 30, 2026, which update shareholder nomination and proposal procedures and address director interests in transactions.
Net sales were $450.7 million, up from $419.1 million; Industrial Equipment Division sales rose 12.8% to $271.6 million.
Net income was $30.9 million, down from $31.1 million; diluted EPS was $2.55 versus $2.57.
Adjusted diluted EPS was $2.82 versus $2.63, an increase of 7.2%; restructuring expenses were $4.0 million versus $0.6 million.
Amended and restated bylaws took effect July 30, 2026, covering director nominations, director compensation and transactions where a director has an interest.
New Jersey Resources reported fiscal third-quarter 2026 net income of $9.7 million, or $0.10 per share, compared with a net loss of $15.1 million, or $0.15 per share, a year earlier. The company narrowed its fiscal 2026 net financial earnings per share guidance to $3.52 to $3.62 from $3.48 to $3.63, raising the low end.
Q3 net income $9.7 million ($0.10 per share) versus a net loss of $15.1 million ($0.15 per share) in the same quarter of fiscal 2025.
Q3 net financial earnings (non-GAAP) $11.3 million ($0.11 per share) versus $6.2 million ($0.06 per share) a year earlier.
Fiscal 2026 NFEPS guidance tightened to $3.52 to $3.62 from $3.48 to $3.63.
Nine-month net income $351.1 million ($3.48 per share) versus $320.6 million ($3.20 per share); results webcast August 4, 2026 at 10 a.m. ET.
On July 31, 2026, Alzamend Neuro agreed to sell up to $25 million of its newly designated Series D convertible preferred stock to Ault Lending, LLC, which the filing says is an affiliate of the company. The company sold $7.5 million of preferred at an initial closing, and the purchaser agreed to buy $2.5 million more later, with up to $15 million in further tranches permitted. Conversion into common stock could dilute existing shareholders, and the company must seek stockholder approval for conversion shares above the Nasdaq 19.99% limit.
Initial tranche: 7,500 Series D preferred shares sold for $7.5 million on July 31, 2026; second tranche of $2.5 million agreed
Conversion price is the greater of a $0.2668 floor and 80% of the lowest closing bid in the prior five trading days, capped at $2.00 per share
Company must file a resale registration statement by the earlier of five days after its 10-K filing or August 15, 2026, and seek stockholder approval for conversion shares above 19.99% of common stock outstanding
Registration default would trigger cash payments to the purchaser of 2% of stated value monthly, capped at 15%
BWX Technologies reported second-quarter 2026 revenue of $901.6 million, up 18% from a year earlier, and GAAP diluted EPS of $0.97, up from $0.85. The company raised its 2026 guidance for adjusted EBITDA, non-GAAP EPS and free cash flow, and said the guidance includes the Precision Components Group acquisition, which closed July 1, 2026.
Q2 2026 revenue was $901.6 million, up from $764.0 million; Commercial Operations revenue rose 72% to $302.5 million.
GAAP diluted EPS was $0.97 versus $0.85; non-GAAP diluted EPS was $1.07 versus $1.02.
2026 guidance: adjusted EBITDA raised to $662 million-$672 million from $650 million-$665 million; non-GAAP EPS raised to $4.70-$4.80 from $4.60-$4.75.
Q2 free cash flow was $115.0 million, down 9% from $126.3 million; Government Operations operating income fell 3% to $105.7 million.
Tidewater reported second-quarter 2026 revenue of $342.3 million, roughly flat from $341.4 million a year earlier, but net income fell to $21.7 million ($0.43 per diluted share) from $72.9 million ($1.46) in the same quarter of 2025. The company also revised its 2026 revenue guidance to $1.42 billion to $1.47 billion and gross margin guidance to 49% to 50%, reflecting a delayed closing of the WSUT acquisition and Middle East conflict costs.
Q2 2026 revenue $342.3 million versus $341.4 million in Q2 2025; up 4.9% from Q1 2026.
Q2 2026 net income $21.7 million ($0.43 diluted) versus $72.9 million ($1.46 diluted) a year earlier.
Average day rate rose $655 per day (2.9%) from Q1 2026 to $22,938; weighted average leading edge day rate was $24,341.
2026 revenue guidance set at $1.42 billion to $1.47 billion; WSUT acquisition now expected to close around September 1, 2026; about $13.1 million of conflict-related costs expected in 2026.
Amneal Pharmaceuticals LLC, a subsidiary of Amneal Pharmaceuticals, Inc., entered into Amendment No. 3 to its Term Loan Credit Agreement on August 3, 2026, reducing the interest rate margin on its term loans by 50 basis points. The company estimates annualized cash interest savings of approximately $12 million compared with the prior agreement, based on amounts outstanding before the amendment.
Existing term loans converted into new term loans with an aggregate principal amount of $2.039 billion
A new $45.2 million term loan was incurred, with proceeds used to prepay remaining existing term loans at par
Margin reduced to 1.50% for base rate loans and 2.50% for SOFR-based loans; stated maturity remains August 1, 2032
Estimated annualized cash interest savings of approximately $12 million; no prepayment premium on a repricing after February 3, 2027
Powell Industries reported fiscal 2026 third-quarter results for the period ended June 30, 2026, with revenue up 9% to $312 million and diluted earnings per share up 8% to $1.42. New orders of $934 million and backlog of $2.4 billion both rose sharply from a year earlier, and the company's board declared a quarterly dividend of $0.09 per share.
Net income was $52.2 million, or $1.42 per diluted share, up 8% from $1.32 a year earlier.
New orders totaled $934 million, up 158% from $362 million in the prior-year quarter; backlog reached $2.4 billion as of June 30, 2026, up 69%.
The board declared a $0.09 per share quarterly cash dividend, payable September 16, 2026, to shareholders of record on August 19, 2026.
Management is conference-calling on August 4, 2026 at 11:00 a.m. Eastern time.
Danaher's board appointed Julie Sawyer Montgomery, currently Executive Vice President and head of the Diagnostics platform, as President and Chief Executive Officer effective October 1, 2026, and she joins the board at that time. Rainer Blair steps down as CEO and director and will serve as a senior advisor during the transition. The company said its third-quarter and full-year 2026 guidance is unchanged.
Sawyer Montgomery's base salary as CEO is $1.5 million, with a target annual cash incentive of 200% of base salary.
She will receive a special stock option award with a target value of $20 million, vesting 50% on the fourth and 50% on the fifth anniversary of the August 4, 2026 grant date.
Blair will remain a senior advisor through December 31, 2026, then serve as a consultant until March 31, 2027, and is entitled to severance including 12 months of base salary.
Danaher said there is no change to its previously communicated third-quarter and full-year 2026 guidance.
Addus HomeCare reported second-quarter 2026 net service revenues of $377.4 million, up 8.0% from $349.4 million a year earlier. Net income rose to $27.6 million, or $1.49 per diluted share, from $1.20 per diluted share in the prior-year quarter. Because revenue, profit and per-share earnings all improved, the results point in a favorable direction for shareholders, though the filing gives no forward guidance.
Net service revenues were $377.4 million, up 8.0% from $349.4 million in Q2 2025
Net income was $27.6 million, or $1.49 per diluted share, versus $1.20 a year earlier
Adjusted EBITDA rose 11.9% to $49.2 million; cash flow from operations was $40.0 million
Results were released August 3, 2026; the conference call is set for August 4, 2026 at 9:00 a.m. Eastern Time
CRISPR Therapeutics reported second quarter 2026 results, with total revenue of $10.2 million versus $0.9 million a year earlier and a net loss of $91.2 million, down from $208.5 million. The company stated CASGEVY generated $76 million in second quarter revenue and that the FDA approved CASGEVY for children 2 years and older, while cash and marketable securities totaled $2.36 billion at June 30, 2026.
Net loss was $91.2 million, or $0.94 per share, versus a net loss of $208.5 million, or $2.40 per share, in Q2 2025
Total revenue was $10.2 million versus $0.9 million a year earlier; the filing shows $10.0 million of collaboration revenue
Cash, cash equivalents and marketable securities were $2,364.4 million at June 30, 2026, including $585.4 million of net proceeds from convertible senior notes issued in March 2026
Acquired in-process R&D expense fell to $2.5 million from $96.3 million, which the company linked to the 2025 Sirius Agreement
Diversified Healthcare Trust reported a second quarter 2026 net loss of $37.4 million, or $0.16 per share, compared with a net loss of $91.6 million, or $0.38 per share, a year earlier. Revenue fell to $365.4 million from $382.7 million, while normalized FFO rose to $38.9 million, and the company said its updated full year 2026 guidance is consistent with its June 1, 2026 release.
Net loss was $37.4 million, or $0.16 per share, for the quarter ended June 30, 2026, versus $91.6 million, or $0.38 per share, a year earlier.
Total revenues were $365.4 million, down from $382.7 million in the second quarter of 2025.
Normalized FFO was $38.9 million, or $0.16 per share, up 109.4% year over year.
Full year 2026 normalized FFO guidance is $135 million to $150 million, consistent with the June 1, 2026 release.
JBT Marel reported second quarter 2026 results with revenue up 5% to $981 million and diluted EPS of $0.54 versus $0.07 a year earlier. Results included a $33 million non-cash impairment charge, and the Prepared Food and Beverage Solutions segment came in below company expectations, while full-year revenue and adjusted EBITDA margin guidance was reiterated.
Q2 2026 revenue $981 million, up 5%; net income $28 million versus $3 million a year earlier
Diluted EPS $0.54 versus $0.07; adjusted EPS $1.95 versus $1.49
Prepared Food and Beverage Solutions revenue was flat at $514 million and adjusted EBITDA margin fell 70 basis points
FY 2026 adjusted EPS guidance refined to $7.85 - $8.35; GAAP diluted EPS guidance updated to $4.20 - $4.70
SBA Communications reported second quarter 2026 net income attributable to SBA of $198.8 million, or $1.87 per diluted share, down from $2.09 a year earlier, while site leasing revenue rose to $663.9 million from $631.8 million. It raised the midpoint of its full year 2026 site leasing revenue outlook by $2.0 million and declared a $1.25 per share quarterly dividend, so shareholders see higher revenue and a slightly higher outlook alongside lower per-share profit.
Diluted EPS was $1.87 versus $2.09; net income included an $8.0 million currency gain versus $30.4 million a year earlier.
Site leasing revenue was $663.9 million, up 5.1%; site development revenue was $51.4 million, down 23.5%.
Full year 2026 AFFO per share outlook is $11.95 to $12.40, with the midpoint up $0.02 from April 29, 2026.
Quarterly cash dividend of $1.25 per share is payable September 17, 2026 to holders of record on August 20, 2026.
ONEOK reported second-quarter 2026 net income of $967 million, up 13% from a year earlier, and diluted earnings of $1.53 per share, up from $1.34. The company also increased its 2026 guidance for net income, earnings per share and adjusted EBITDA, its second guidance increase this year.
Q2 2026 adjusted EBITDA was $2.12 billion, up 7% from $1.98 billion in Q2 2025.
2026 net income guidance was raised to a range of $3.41 billion to $3.79 billion; adjusted EBITDA guidance to $8.2 billion to $8.5 billion.
Diluted EPS guidance midpoint was raised to $5.68; 2026 capital expenditure guidance of about $2.7 billion to $3.2 billion was unchanged.
In July 2026 the company declared a quarterly dividend of $1.07 per share, or $4.28 annualized.
Crescent Energy reported second-quarter 2026 revenue of $1.39 billion, up from $898 million a year earlier, and net income attributable to the company of $492.8 million, up from $153.2 million. The company raised its 2026 total and oil production guidance and lowered its adjusted operating expense and production tax guidance, while keeping its development capital outlook unchanged.
Q2 2026 revenue was $1.39 billion versus $898 million in Q2 2025; diluted EPS was $1.30 versus $0.60.
Record operating cash flow of $707 million and record levered free cash flow of $418 million in the quarter.
2026 total production guidance raised to 327-335 MBoe/d from 320-335 MBoe/d; adjusted opex guidance lowered to $11.00-$12.00/Boe from $11.50-$12.50/Boe.
Quarterly dividend of $0.12 per share payable August 31, 2026; about $336 million remains on the share repurchase program.
Boise Cascade reported second-quarter 2026 sales up 5% to $1.8 billion, while net income fell 7% to $57.3 million and diluted earnings per share slipped to $1.63 from $1.64. The company also disclosed a 10-year agreement making its distribution subsidiary the sole full-line national distributor of James Hardie's exterior building products, and gave third-quarter Adjusted EBITDA guidance of about $82 million to $114 million.
Q2 2026 sales were $1.83 billion, up 5% from $1.74 billion a year earlier; net income was $57.3 million, or $1.63 per diluted share, versus $62.0 million, or $1.64, in Q2 2025.
Q2 2026 Adjusted EBITDA was $126.2 million, up 6%; Q2 2025 results included $5.8 million of after-tax gains on property sales.
Q3 2026 guidance: total Company Adjusted EBITDA of about $82 million to $114 million.
Distribution agreement with James Hardie, effective July 31, 2026, has a 10-year initial term; Boise Cascade has guaranteed its subsidiary's obligations under the agreement.
Korn Ferry entered into a Deed of Amendment dated July 29, 2026, to its June 27, 2026 Purchase and Sale Agreement for the acquisition of Auxey Holdco Limited. Under the amendment, the acquisition is to close on September 1, 2026, provided all closing conditions are satisfied or waived by August 27, 2026; otherwise the amendment has no effect and the original closing terms apply. The filing does not state the purchase price, and the closing is not assured, as it depends on conditions and regulatory approvals.
Deed of Amendment entered into July 29, 2026, with Auxey Holdings (Lux) S.A.S., OMERS Administration Corporation, AMS Cayco Ltd. and other parties
Target closing date of September 1, 2026, if closing conditions are satisfied or waived by August 27, 2026
If conditions are not met by August 27, 2026, the amendment lapses and the original Purchase Agreement timing applies
The filing does not disclose the purchase price; the full amendment is filed as Exhibit 2.1
Jackson Financial reported second quarter 2026 net income of $644 million, or $9.16 per diluted share, versus $168 million, or $2.34, a year earlier. Adjusted operating earnings, which the company says better reflect underlying performance, rose to a record $7.30 per diluted share from $4.87, helped by higher spread and fee income and a lower share count from buybacks.
Net income attributable to common shareholders was $644 million, or $9.16 per diluted share, compared with $168 million, or $2.34, in Q2 2025.
Adjusted operating earnings were $513 million, or a record $7.30 per diluted share, compared with $350 million, or $4.87, in Q2 2025.
Retail annuity sales were $5.9 billion, up 34% from Q2 2025, including record RILA sales of $2.3 billion.
The company returned $290 million to common shareholders in the quarter, including $227 million of share repurchases and $63 million in dividends.
Crawford & Company reported second-quarter 2026 revenues before reimbursements of $321.4 million, down slightly from $323.0 million a year earlier, while GAAP net income rose 73% to $13.4 million. The Board approved an increase in the quarterly dividend to $0.08 per share, and the company said its International Operations and Broadspire segments drove the results.
Revenues before reimbursements were $321.4 million versus $323.0 million in Q2 2025.
Diluted EPS for CRD-A was $0.27 versus $0.16; non-GAAP diluted EPS was $0.38 versus $0.22.
International Operations operating earnings rose to $10.9 million from $7.3 million, with operating margin at 7.9% versus 5.5%.
Q2 2026 included a $2.3 million software impairment and a $1.3 million net loss on disposition of businesses.
Williams reported second-quarter 2026 GAAP net income of $827 million, or $0.68 per diluted share, up 51% from a year earlier, and raised its 2026 Adjusted EBITDA guidance midpoint by $200 million to $8.4 billion. The company also agreed to acquire Momentum Midstream for up to $5.5 billion, which would expand its Haynesville natural gas footprint and is subject to customary closing conditions, including Hart-Scott-Rodino clearance.
Q2 2026 GAAP net income $827 million ($0.68 per diluted share), up 51% vs. Q2 2025; Adjusted EBITDA $1.921 billion, up 6%
Adjusted net income $614 million ($0.50 per diluted share), up 8% vs. Q2 2025
2026 Adjusted EBITDA guidance now $8.3 billion to $8.5 billion, midpoint raised by $200 million to $8.4 billion
Momentum Midstream deal valued at up to $5.5 billion (about $3.5 billion cash and debt, roughly $2 billion Williams equity); earnings call Tuesday, Aug. 4, 9:30 a.m. Eastern
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.